SLC16A1 and Alzheimer disease: As shown in Figure 6F–I, in both the colon and the brain, the expression levels of MCT-1 in the model group significantly decreased compared with the normal group (p < 0.05 and p < 0.05), while SCEP treatment significantly increased the levels of MCT-1 in AlCl3/D-gal-induced AD model mice (p < 0.01 and p < 0.01).